| Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 ME Reff, K Carner, KS Chambers, PC Chinn, JE Leonard, R Raab, ... | 2712 | 1994 |
| Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma DR Anderson, N Hanna, JE Leonard, RA Newman, ME Reff, WH Rastetter US Patent 5,736,137, 1998 | 1000* | 1998 |
| Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma DR Anderson, N Hanna, JE Leonard, RA Newman, ME Reff, WH Rastetter US Patent 5,776,456, 1998 | 388 | 1998 |
| Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma DR Anderson, N Hanna, JE Leonard, RA Newman, ME Reff, WH Rastetter US Patent 5,843,439, 1998 | 226 | 1998 |
| Rituximab the first monoclonal antibody approved for the treatment of lymphoma AJ Grillo-Lopez, CA White, BK Dallaire, CL Varns, CD Shen, A Wei, ... Current pharmaceutical biotechnology 1 (1), 1-9, 2000 | 187 | 2000 |
| Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. PC Chinn, JE Leonard, J Rosenberg, N Hanna, DR Anderson International journal of oncology 15 (5), 1017-1042, 1999 | 127 | 1999 |
| SEMA4D compromises blood–brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease ES Smith, A Jonason, C Reilly, J Veeraraghavan, T Fisher, M Doherty, ... Neurobiology of Disease 73, 254-268, 2015 | 112 | 2015 |
| Therapeutic application of chimeric and radiolabelled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma D Anderson, N Hanna, J Leonard, R Newman, M Reff, W Rastetter US Patent App. 09/905,928, 2003 | 95 | 2003 |
| Therapeutic application of chimeric and radiolabelled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma D Anderson, N Hanna, J Leonard, R Newman, M Reff, W Rastetter US Patent App. 09/911,703, 2002 | 80 | 2002 |
| Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restriced differentiation antigen for treatment of B cell lymphoma D Anderson, N Hanna, J Leonard, R Newman, M Reff, W Rastetter US Patent App. 09/911,692, 2003 | 73 | 2003 |
| A humanized anti-human CD154 monoclonal antibody blocks CD154–CD40 mediated human B cell activation P Brams, A Black, EA Padlan, K Hariharan, J Leonard, K Chambers-Slater, ... International immunopharmacology 1 (2), 277-294, 2001 | 70 | 2001 |
| Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma D Anderson, N Hanna, J Leonard, R Newman, M Reff, W Rastetter US Patent App. 10/238,681, 2003 | 69 | 2003 |
| Mannitol-specific enzyme II of the bacterial phosphotransferase system. II. Reconstitution of vectorial transphosphorylation in phospholipid vesicles. JE Leonard, MH Saier Jr Journal of Biological Chemistry 258 (17), 10757-10760, 1983 | 69 | 1983 |
| Mannitol-specific enzyme II of the bacterial phosphotransferase system. I. Properties of the purified permease. GR Jacobson, CA Lee, JE Leonard, MH Saier Journal of Biological Chemistry 258 (17), 10748-10756, 1983 | 68 | 1983 |
| Safety, pharmacokinetics, and pharmacodynamics of a humanized anti-semaphorin 4D antibody, in a first-in-human study of patients with advanced solid tumors A Patnaik, GJ Weiss, JE Leonard, DW Rasco, JC Sachdev, TL Fisher, ... Clinical Cancer Research 22 (4), 827-836, 2016 | 67 | 2016 |
| Use of chimeric anti-cd20 antibody as in vitro or in vivo purging agent in patients receiving bmt or pbsc transplant AJ Grillo-López, J Leonard US Patent App. 13/051,054, 2011 | 59 | 2011 |
| Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial C LaGanke, L Samkoff, K Edwards, L Jung Henson, P Repovic, S Lynch, ... Neurology: Neuroimmunology & Neuroinflammation 4 (4), e367, 2017 | 56 | 2017 |
| A PrimatizedMAb to Human CD4 Causes Receptor Modulation, without Marked Reduction in CD4+ T Cells in Chimpanzees: In Vitroandin VivoCharacterization of a MAb (IDEC-CE9. 1) to … D Anderson, K Chambers, N Hanna, J Leonard, M Reff, R Newman, ... Clinical immunology and immunopathology 84 (1), 73-84, 1997 | 56 | 1997 |
| Preclinical studies on the use of selective antibody-ricin conjugates in autologous bone marrow transplantation JE Leonard, R Taetle, D To, K Rhyner | 53 | 1985 |
| Radiolabeling kit and binding assay P Chinn, R Morena, M Labarre, JE Leonard US Patent App. 09/259,337, 2002 | 48 | 2002 |
